验证MiROvaR——一种基于微小RNA的早期上皮性卵巢癌早期复发预测工具,作为优化患者预后评估的新策略
本研究在独立队列中回顾性验证基于组织的miRNA签名MiROvaR对早期上皮性卵巢癌(eEOC)复发的预测能力。87例可评估患者中,MiROvaR将68例(78%)归为低风险、19例(22%)归为高风险;高风险组5年复发率为39%,低风险组为9.5%。MiROvaR可显著预测5年无进展生存(HR=5.43,95%CI 1.82-16.1,p=0.0024),而临床变量均无预后相关性。
要点
- MiROvaR在早期上皮性卵巢癌中可区分高风险与低风险复发人群。
- 高风险组5年复发率39%,低风险组9.5%。
- MiROvaR预测5年复发的HR为5.43(95%CI 1.82-16.1)。
核心结论
- MiROvaR在早期上皮性卵巢癌诊断时可识别早期复发高风险患者,从而有助于选择最有效的治疗策略。
研究设计与样本
- 回顾性研究,纳入本机构接受全面手术分期的IA至IIB期早期上皮性卵巢癌患者89例,最终87例可评估MiROvaR。
- 中位随访时间为112个月。
主要发现
- MiROvaR将68例(78%)归为低风险、19例(22%)归为高风险。
- 5年主要终点复发率:高风险组39% vs 低风险组9.5%。
- Kaplan-Meier无进展生存曲线在主要终点分析(p=0.0006)和次要分析(p=0.03)均显著不同。
- 5年主要终点分析:MiROvaR预测复发的HR=5.43(95%CI 1.82-16.1,p=0.0024),AUC=0.78(95%CI 0.53-0.82)。
- 完整随访分析:HR=2.67(95%CI 1.04-6.8,p=0.041),AUC=0.68(95%CI 0.52-0.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Early-stage epithelial ovarian cancer (eEOC) patients have a generally favorable prognosis but unpredictable recurrence. Accurate prediction of risk of relapse is still a major concern, essentially to avoid overtreatment. Our robust tissue-based miRNA signature named MiROvaR, predicting early EOC recurrence in mostly advanced-stage EOC patients, is here challenged in an independent cohort to extend its classifying ability in the early-stage EOC setting. METHODS: We retrospectively selected patients who underwent comprehensive surgical staging at our institution including stages from IA to IIB. miRNA expression profile was analysed in 89 cases and MiROvaR algorithm was applied using the previously validated cut-off for patients' classification. The primary endpoint was progression-free survival (PFS) at 5 years. Complete follow-up time (median = 112 months) was also considered as secondary analysis. RESULTS: MiROvaR was assessable on 87 cases (19 events of disease progression) and classified 68 (78%) low-risk and 19 (22%) high-risk patients. Recurrence rate at primary end-point was 39% for high-risk patients as compared to 9.5% for low-risk ones. Accordingly, their Kaplan-Meier PFS curves were significantly different at both primary and secondary analysis (p = 0.0006 and p = 0.03, respectively). While none of the prominent clinical variables had prognostic relevance, MiROvaR significantly predicted disease recurrence at the 5-year assessment (primary endpoint analysis; HR:5.43, 95%CI:1.82-16.1, p = 0.0024; AUC = 0.78, 95%CI:0.53-0.82) and at complete follow-up time (HR:2.67, 95%CI:1.04-6.8, p = 0.041; AUC:0.68, 95%CI:0.52-0.82). CONCLUSIONS: We validated MiROvaR performance in identifying at diagnosis eEOC patients' at higher risk of early relapse thus enabling selection of the most effective therapeutic approach.
引用
- Ditto A, De Cecco L, Paolini B, et al. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. Eur J Cancer. 2021. PMID: 34922264. doi:10.1016/j.ejca.2021.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。